Prognostic value of galectin-3 in patients with heart failure

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Bošnjak, Ivica ^a   Selthofer Relatic, Kristina ^a,b   Včev, Aleksandar ^a,b  

^a Health Centre Osijek   (Croatia)

^b JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; GALECTIN 3; RENIN; TRANSFORMING GROWTH FACTOR BETA; TROPONIN I; TROPONIN T; BIOLOGICAL MARKER;

CARDIORENAL SYNDROME; CELL PROLIFERATION; CHRONIC PANCREATITIS; CORONARY ARTERY DISEASE; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HEART EJECTION FRACTION; HEART FAILURE; HEART FIBROBLAST; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC CARDIOMYOPATHY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER CIRRHOSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC HEART FAILURE; ANIMAL; BLOOD; METABOLISM;

ANIMALS; BIOMARKERS; GALECTIN 3; HEART FAILURE; HUMANS;

EID: 84928798484     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/690205     Document Type: Review

References (49)

1. M. Gheorghiade and P. S. Pang, "Acute Heart Failure Syndromes, " Journal of the American College of Cardiology, vol. 53, no. 7, pp. 557-573, 2009.
2. R. S. Velagaleti and R. S. Vasan, "Epidemiology of heart failure, " in Heart: A Companion to Braunwald's Heart Disease, D. L. Mann, Ed. , pp. 346-354, Elsevier, Saint Louis, Mo, USA, 2nd edition, 2011.
3. J. T. Thibodeau, A. T. Turer, S. K. Gualano et al. , "Characterization of a novel symptomof advanced heart failure: bendopneas, " JACC: Heart Failure, vol. 2, no. 1, pp. 24-31, 2014.
4. K. Dickstein, A. Cohen-Solal, G. Filippatos et al. , "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), " European Heart Journal, vol. 10, no. 10, pp. 933-989, 2008.
5. J. J. McMurray, S. Adamopoulos, S. D. Anker et al. , "ESC guidelines for diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, " European Journal of Heart Failure, vol. 14, pp. 803-869, 2012.
6. S. A. Hunt, W. T. Abraham, M. H. Chin, and et al, "2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of the heart failure in adults: a report of the AmericanCollege of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplanation, " Circulation, vol. 119, pp. e391-e479, 2009.
7. V. V. Michels, P. P. Moll, F. A. Miller et al. , "The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy, " The New England Journal of Medicine, vol. 326, no. 2, pp. 77-82, 1992.
8. E. E. Creemers and Y. M. Pinto, "Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart, " Cardiovascular Research, vol. 89, no. 2, pp. 265-272, 2011.
9. J. Seetharaman, A. Kfanigsberg, R. Slaaby, H. Leffler, S. H. Barondes, and J. M. Rini, "X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2. 1-?A resolution, "The Journal of Biological Chemistry, vol. 273, no. 21, pp. 13047-13052, 1998.
10. E. A. M. Barboni, S. Bawumia, K. Henrick, and R. C. Hughes, "Molecular modeling and mutagenesis studies of the Nterminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding, " Glycobiology, vol. 10, no. 11, pp. 1201-1208, 2000.
11. J. Dumic, S. Dabelic, and M. Flgel, "Galectin-3: an open-ended story, " Biochimica et Biophysica Acta, vol. 1760, no. 4, pp. 616-635, 2006.
12. H. Sano, D. K. Hsu, J. R. Apgar et al. , "Critical role of galectin-3 in phagocytosis by macrophages, " The Journal of Clinical Investigation, vol. 112, no. 3, pp. 389-397, 2003.
13. M. J. Elliott, A. Strasser, andD. Metcalf, "Selective up-regulation of macrophage function in granulocyte-macrophage colonystimulating factor transgenic mice, "The Journal of Immunology, vol. 147, no. 9, pp. 2957-2963, 1991.
14. U. C. Sharma, S. Pokharel, T. J. van Brakel et al. , "Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, " Circulation, vol. 110, no. 19, pp. 3121-3128, 2004.
15. U. Sharma, N.-E. Rhaleb, S. Pokharel et al. , "Novel antiinflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 294, no. 3, pp. H1226-H1232, 2008.
16. N. C. Henderson, A. C. Mackinnon, S. L. Farnworth et al. , "Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis, " American Journal of Pathology, vol. 172, no. 2, pp. 288-298, 2008.
17. N. C. Henderson, A. C. Mackinnon, S. L. Farnworth et al. , "Galectin-3 regulates myofibroblast activation and hepatic fibrosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, pp. 5060-5065, 2006.
18. K. Reifenberg, H.-A. Lehr, M. Torzewski et al. , "Interferon-induces chronic active myocarditis and cardiomyopathy in transgenic mice, " American Journal of Pathology, vol. 171, no. 2, pp. 463-472, 2007.
19. B. Schroen, S. Heymans, U. Sharma et al. , "Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy, " Circulation Research, vol. 95, no. 5, pp. 515-522, 2004.
20. S. L. Friedman, "Molecular regulations of hepatic fibrosis, an integrated cellular response to tissue injury, " The Journal of Biological Chemistry, vol. 275, no. 4, pp. 2247-2250, 2000.
21. J. S. Duffield, S. J. Forbes, C. M. Constandinou et al. , "Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair, " Journal of Clinical Investigation, vol. 115, no. 1, pp. 56-65, 2005.
22. D. K. Hsu, C. A. Dowling, K. C. Jeng, J. T. Chen, R. Y. Yang, and F. T. Liu, "Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma, " International Journal of Cancer, vol. 81, no. 4, pp. 519-526, 1999.
23. Y. Nishi, H. Sano, T. Kawashima et al. , "Role of galectin-3 in human pulmonary fibrosis, " Allergology International, vol. 56, no. 1, pp. 57-65, 2007.
24. S. Sasaki, Q. Bao, and R. C. Hughes, "Galectin-3 modualtes rat mesengial cell proliferation andmatrix synthesis during experimental glomerulonephritis induced by anti-Thy1. 1 antibodies, " The Journal of Pathology, vol. 187, pp. 481-489, 1999.
25. H.-J. Anders, V. Vielhauer, M. Frink et al. , "A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation, "The Journal of Clinical Investigation, vol. 109, no. 2, pp. 251-259, 2002.
26. V. Eis, B. Luckow, V. Vielhauer et al. , "Chemokine receptor CCR1 but nor CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral obstruction, " Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 337-347, 2004.
27. K. Kitagawa, T. Wada, K. Furuichi et al. , "Blockade of CCR2 ameliorates progressive fibrosis in kidney, " The American Journal of Pathology, vol. 165, no. 1, pp. 237-246, 2004.
28. H. R. Zandbergen, U. C. Sharma, S. Gupta et al. , "Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy, " Journal of Cardiovascular Pharmacology and Therapeutics, vol. 14, no. 1, pp. 68-75, 2009.
29. J. J. V. McMurray, "Systolic heart failure, " The New England Journal of Medicine, vol. 362, no. 3, pp. 228-238, 2010.
30. W. H. Gaasch andM. R. Zile, "Left ventricular diastolic dysfunction and diastolic heart failure, " Annual Review ofMedicine, vol. 55, pp. 373-394, 2004.
31. P. Abrahamsson, J. Dobson, C. B. Granger et al. , "Impact of hospitalization for acute coronary events on subsequent mortality in patientswith chronic heart failure, " EuropeanHeart Journal, vol. 30, no. 3, pp. 338-345, 2009.
32. G. P. Aurigemma and W. H. Gaasch, "Diastolic heart failure, " The New England Journal of Medicine, vol. 351, no. 11, pp. 1097-1157, 2004.
33. Y.-H. Liu, M. D'Ambrosio, T. D. Liao et al. , "N-acetylseryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 2, pp. H404-H412, 2009.
34. P. A. McCullough, A. Olobatoke, andT. E. Vanhecke, "Galectin-3: a novel blood test for the evaluation and management of patients with heart failure, " Reviews in CardiovascularMedicine, vol. 12, no. 4, pp. 200-210, 2011.
35. M. R. Zile, S. M. De Santis, C. F. Baicu et al. , "Plasma galectin-3 levels in patinets with structural and clinical manifestation of hypertensive heart disease: relationship to determination of matrix composition, " Circulation, vol. 122, Article ID A12433, 2010.
36. R. A. de Boer, A. A. Voors, P. Muntendam, W. H. van Gilst, and D. J. van Veldhuisen, "Galectin-3: a novel mediator of heart failure development and progression, " European Journal of Heart Failure, vol. 11, no. 9, pp. 811-817, 2009.
37. G. Savarese, B. Trimarco, S. Dellegrottaglie et al. , "Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2, 686 patients in 12 randomized trials, " PLoS ONE, vol. 8, no. 3, Article ID e58287, 2013.
38. R. D. Kociol, P. S. Pang, M. Gheorghiade, G. C. Fonarow, C. M. O'Connor, and G. M. Felker, "Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications, " Journal of the American College of Cardiology, vol. 56, no. 14, pp. 1071-1078, 2010.
39. A. Tanindi and M. Cemri, "Troponin elevation in conditions other than acute coronary syndromes, "VascularHealth and Risk Management, vol. 7, no. 1, pp. 597-603, 2011.
40. D. J. A. Lok, P. van der Meer, P. W. B.-A. de la Porte et al. , "Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study, " Clinical Research in Cardiology, vol. 99, no. 5, pp. 323-328, 2010.
41. D. Lok, P. van der Meer, P. B. de la Porte et al. , "Galectin-3, a novel marker of macrophage activity, predicts outcome in patients with stabile chronic heart failure, " Journal of the American College of Cardiology A, vol. 49, article 98, 2007, (abstract).
42. R. R. van Kimmenade, J. L. Januzzi Jr. , P. T. Ellinor et al. , "Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patientswith acute heart failure, " Journal of the American College of Cardiology, vol. 48, no. 6, pp. 1217-1224, 2006.
43. H. Milting, P. Ellinghaus, M. Seewald et al. , "Plasma biomarkers ofmyocardial fibrosis and remodelling in terminal heart failure patients supported by mechanical circulatory support devices, " Journal of Heart and Lung Transplantation, vol. 27, no. 6, pp. 589-596, 2008.
44. E. W. Grandin, P. Jarolim, S. A. Murphy et al. , "Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22, " Clinical Chemistry, vol. 58, no. 1, pp. 267-273, 2012.
45. T.-H. Tsai, P.-H. Sung, L.-T. Chang et al. , "Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention, " Journal of Atherosclerosis and Thrombosis, vol. 19, no. 12, pp. 1073-1082, 2012.
46. L. Wang, H. Friess, Z. Zhu et al. , "Galectin-1 and galectin-3 in chronic pancreatitis, " Laboratory Investigation, vol. 80, no. 8, pp. 1233-1241, 2000.
47. D. K. Hsu, C. A. Dowling, K. C. Jeng, J. T. Chen, R. Y. Yang, and F. T. Liu, "Galectin-3 expression is induced in cirrhotic liver and Hepatocellular carcinoma, " International Journal of Cancer, vol. 81, no. 4, pp. 519-526, 1999.
48. Y. Nishi, H. Sano, T. Kawashima et al. , "Role of galectin-3 in human pulmonary fibrosis, " Allergology International, vol. 56, no. 1, pp. 57-65, 2007.
49. R. A. De Boer, D. J. A. Lok, T. Jaarsma et al. , "Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction, " Annals of Medicine, vol. 43, no. 1, pp. 60-68, 2011.